Dr. Guo Feng has been responsible for the overall management, business and strategy of Genor Biopharma since April 2020 as Chief Executive Officer, Executive Director of the Board. And he has been appointed Chairman of the Board in November 2021.

Dr. Guo has more than 20 years’ experience in the biopharmaceutical industry.

Prior to joining Genor Biopharma, Dr. Guo worked at Merck as VP and Head of Merck China R&D Hub; at Pfizer as Head of Pfizer (Wuhan) Research and Development Centre; and at Xuanzhu (Beijing) Pharmaceutical Technology Ltd as Chairman of the board.

Dr. Guo obtained a Ph.D. in clinical pharmacology from the University of Toronto in Canada.

25+ years of academic research and drug discovery experience, especially in the fields of oncology, immune-oncology, inflammation and autoimmune diseases.

Previously worked at Shanghai WuXi AppTec as Vice President of drug discovery and at Baylor College of Medicine as tenured professor of immunology and pathology.

Former senior director and head of the clinical development department at Janssen, prior to which also worked at Merck and Pfizer

An outstanding expert in biologics development, production and management.

30 years of experience in the operation and management in the CMC and production departments of internationally renowned biopharmaceutical companies such as Genentech Inc., Bayer Corporation and Progenics Pharmaceuticals.

Led the establishment and operation of 3 Chinese biopharmaceutical companies, including Wuxi AppTec, MabPlex International and CMAB Biopharma Inc.

Over 20 years regulatory affairs experience in multiple leading big pharma and biopharma companies, with excellent insight of China and global regulatory landscape.

The former Head of Regulatory Affairs of China & HK region in AbbVie, headed the regulatory strategy development and regulatory activities and led a number of CTA and NDA applications and approvals.